Resistance of cancers to immunologic cytotoxicity and adoptive immunotherapy via X-linked inhibitor of apoptosis protein expression and coexisting defects in mitochondrial death signaling

Rajani Ravi, Ephraim J. Fuchs, Ajay Jain, Vui Pham, Kiyoshi Yoshimura, Traci Prouser, Sanju Jalla, Xianzheng Zhou, Elizabeth Garrett-Mayer, Scott H Kaufmann, Richard D. Schulick, Drew M. Pardoll, Atul Bedi

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

The ability of cancers to evade immune surveillance and resist immunotherapy raises a fundamental question of how tumor cells survive in the presence of a competent immune system. Studies to address this question have primarily focused on mechanisms by which tumor cells avoid recognition by or induce tolerance in the immune system. However, little is known about whether cancer cells also acquire an intrinsic ability to resist killing by immune effectors. We find that cancer cells enhance their ability to withstand an attack by cytotoxic immune effector cells via acquisition of specific genetic alterations that interfere with the shared mitochondrial death signaling pathway entrained by granzyme B, IFN-γ, and Apo2 ligand/tumor necrosis factor-related apoptosis inducing ligand (Apo2L/TRAIL), three key mediators of immunologic cell-mediated cytotoxicity. We show that the coexistence of specific mitochondrial signaling defects (either deletion of Bax, overexpression of Bcl-xL, or deletion of Smac) with expression of X-linked inhibitor of apoptosis protein decreases the sensitivity of cancer cells to IFN-γ/Apo2L/TRAIL- or granzyme B-induced apoptosis, lymphocyte-mediated cytotoxicity in vitro, and adoptive cellular immunotherapy in vivo. Conversely, negating X-linked inhibitor of apoptosis protein expression or function in tumor cells with defective mitochondrial signaling enables direct activation of caspase-3/-7 by granzyme B or Apo2L/TRAIL, and restores their susceptibility to immunologic cytotoxicity. These findings identify an important mechanism by which cancers evade elimination by immune effector cells and suggest that cancer immunotherapy might be improved by concurrent strategies to alleviate or circumvent the intrinsic mitochondrial death signaling defects that help cancer cells resist immunologic cytotoxicity.

Original languageEnglish (US)
Pages (from-to)1730-1739
Number of pages10
JournalCancer Research
Volume66
Issue number3
DOIs
StatePublished - Feb 1 2006

Fingerprint

Immunologic Cytotoxicity
X-Linked Inhibitor of Apoptosis Protein
Adoptive Immunotherapy
Neoplasms
Ligands
Granzymes
Apoptosis
Tumor Necrosis Factor-alpha
Immunotherapy
Immune System
Caspase 7

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Resistance of cancers to immunologic cytotoxicity and adoptive immunotherapy via X-linked inhibitor of apoptosis protein expression and coexisting defects in mitochondrial death signaling. / Ravi, Rajani; Fuchs, Ephraim J.; Jain, Ajay; Pham, Vui; Yoshimura, Kiyoshi; Prouser, Traci; Jalla, Sanju; Zhou, Xianzheng; Garrett-Mayer, Elizabeth; Kaufmann, Scott H; Schulick, Richard D.; Pardoll, Drew M.; Bedi, Atul.

In: Cancer Research, Vol. 66, No. 3, 01.02.2006, p. 1730-1739.

Research output: Contribution to journalArticle

Ravi, R, Fuchs, EJ, Jain, A, Pham, V, Yoshimura, K, Prouser, T, Jalla, S, Zhou, X, Garrett-Mayer, E, Kaufmann, SH, Schulick, RD, Pardoll, DM & Bedi, A 2006, 'Resistance of cancers to immunologic cytotoxicity and adoptive immunotherapy via X-linked inhibitor of apoptosis protein expression and coexisting defects in mitochondrial death signaling', Cancer Research, vol. 66, no. 3, pp. 1730-1739. https://doi.org/10.1158/0008-5472.CAN-05-3377
Ravi, Rajani ; Fuchs, Ephraim J. ; Jain, Ajay ; Pham, Vui ; Yoshimura, Kiyoshi ; Prouser, Traci ; Jalla, Sanju ; Zhou, Xianzheng ; Garrett-Mayer, Elizabeth ; Kaufmann, Scott H ; Schulick, Richard D. ; Pardoll, Drew M. ; Bedi, Atul. / Resistance of cancers to immunologic cytotoxicity and adoptive immunotherapy via X-linked inhibitor of apoptosis protein expression and coexisting defects in mitochondrial death signaling. In: Cancer Research. 2006 ; Vol. 66, No. 3. pp. 1730-1739.
@article{70d6ec137988431f9bf0b05aa2916a5d,
title = "Resistance of cancers to immunologic cytotoxicity and adoptive immunotherapy via X-linked inhibitor of apoptosis protein expression and coexisting defects in mitochondrial death signaling",
abstract = "The ability of cancers to evade immune surveillance and resist immunotherapy raises a fundamental question of how tumor cells survive in the presence of a competent immune system. Studies to address this question have primarily focused on mechanisms by which tumor cells avoid recognition by or induce tolerance in the immune system. However, little is known about whether cancer cells also acquire an intrinsic ability to resist killing by immune effectors. We find that cancer cells enhance their ability to withstand an attack by cytotoxic immune effector cells via acquisition of specific genetic alterations that interfere with the shared mitochondrial death signaling pathway entrained by granzyme B, IFN-γ, and Apo2 ligand/tumor necrosis factor-related apoptosis inducing ligand (Apo2L/TRAIL), three key mediators of immunologic cell-mediated cytotoxicity. We show that the coexistence of specific mitochondrial signaling defects (either deletion of Bax, overexpression of Bcl-xL, or deletion of Smac) with expression of X-linked inhibitor of apoptosis protein decreases the sensitivity of cancer cells to IFN-γ/Apo2L/TRAIL- or granzyme B-induced apoptosis, lymphocyte-mediated cytotoxicity in vitro, and adoptive cellular immunotherapy in vivo. Conversely, negating X-linked inhibitor of apoptosis protein expression or function in tumor cells with defective mitochondrial signaling enables direct activation of caspase-3/-7 by granzyme B or Apo2L/TRAIL, and restores their susceptibility to immunologic cytotoxicity. These findings identify an important mechanism by which cancers evade elimination by immune effector cells and suggest that cancer immunotherapy might be improved by concurrent strategies to alleviate or circumvent the intrinsic mitochondrial death signaling defects that help cancer cells resist immunologic cytotoxicity.",
author = "Rajani Ravi and Fuchs, {Ephraim J.} and Ajay Jain and Vui Pham and Kiyoshi Yoshimura and Traci Prouser and Sanju Jalla and Xianzheng Zhou and Elizabeth Garrett-Mayer and Kaufmann, {Scott H} and Schulick, {Richard D.} and Pardoll, {Drew M.} and Atul Bedi",
year = "2006",
month = "2",
day = "1",
doi = "10.1158/0008-5472.CAN-05-3377",
language = "English (US)",
volume = "66",
pages = "1730--1739",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - Resistance of cancers to immunologic cytotoxicity and adoptive immunotherapy via X-linked inhibitor of apoptosis protein expression and coexisting defects in mitochondrial death signaling

AU - Ravi, Rajani

AU - Fuchs, Ephraim J.

AU - Jain, Ajay

AU - Pham, Vui

AU - Yoshimura, Kiyoshi

AU - Prouser, Traci

AU - Jalla, Sanju

AU - Zhou, Xianzheng

AU - Garrett-Mayer, Elizabeth

AU - Kaufmann, Scott H

AU - Schulick, Richard D.

AU - Pardoll, Drew M.

AU - Bedi, Atul

PY - 2006/2/1

Y1 - 2006/2/1

N2 - The ability of cancers to evade immune surveillance and resist immunotherapy raises a fundamental question of how tumor cells survive in the presence of a competent immune system. Studies to address this question have primarily focused on mechanisms by which tumor cells avoid recognition by or induce tolerance in the immune system. However, little is known about whether cancer cells also acquire an intrinsic ability to resist killing by immune effectors. We find that cancer cells enhance their ability to withstand an attack by cytotoxic immune effector cells via acquisition of specific genetic alterations that interfere with the shared mitochondrial death signaling pathway entrained by granzyme B, IFN-γ, and Apo2 ligand/tumor necrosis factor-related apoptosis inducing ligand (Apo2L/TRAIL), three key mediators of immunologic cell-mediated cytotoxicity. We show that the coexistence of specific mitochondrial signaling defects (either deletion of Bax, overexpression of Bcl-xL, or deletion of Smac) with expression of X-linked inhibitor of apoptosis protein decreases the sensitivity of cancer cells to IFN-γ/Apo2L/TRAIL- or granzyme B-induced apoptosis, lymphocyte-mediated cytotoxicity in vitro, and adoptive cellular immunotherapy in vivo. Conversely, negating X-linked inhibitor of apoptosis protein expression or function in tumor cells with defective mitochondrial signaling enables direct activation of caspase-3/-7 by granzyme B or Apo2L/TRAIL, and restores their susceptibility to immunologic cytotoxicity. These findings identify an important mechanism by which cancers evade elimination by immune effector cells and suggest that cancer immunotherapy might be improved by concurrent strategies to alleviate or circumvent the intrinsic mitochondrial death signaling defects that help cancer cells resist immunologic cytotoxicity.

AB - The ability of cancers to evade immune surveillance and resist immunotherapy raises a fundamental question of how tumor cells survive in the presence of a competent immune system. Studies to address this question have primarily focused on mechanisms by which tumor cells avoid recognition by or induce tolerance in the immune system. However, little is known about whether cancer cells also acquire an intrinsic ability to resist killing by immune effectors. We find that cancer cells enhance their ability to withstand an attack by cytotoxic immune effector cells via acquisition of specific genetic alterations that interfere with the shared mitochondrial death signaling pathway entrained by granzyme B, IFN-γ, and Apo2 ligand/tumor necrosis factor-related apoptosis inducing ligand (Apo2L/TRAIL), three key mediators of immunologic cell-mediated cytotoxicity. We show that the coexistence of specific mitochondrial signaling defects (either deletion of Bax, overexpression of Bcl-xL, or deletion of Smac) with expression of X-linked inhibitor of apoptosis protein decreases the sensitivity of cancer cells to IFN-γ/Apo2L/TRAIL- or granzyme B-induced apoptosis, lymphocyte-mediated cytotoxicity in vitro, and adoptive cellular immunotherapy in vivo. Conversely, negating X-linked inhibitor of apoptosis protein expression or function in tumor cells with defective mitochondrial signaling enables direct activation of caspase-3/-7 by granzyme B or Apo2L/TRAIL, and restores their susceptibility to immunologic cytotoxicity. These findings identify an important mechanism by which cancers evade elimination by immune effector cells and suggest that cancer immunotherapy might be improved by concurrent strategies to alleviate or circumvent the intrinsic mitochondrial death signaling defects that help cancer cells resist immunologic cytotoxicity.

UR - http://www.scopus.com/inward/record.url?scp=32944467254&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=32944467254&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-05-3377

DO - 10.1158/0008-5472.CAN-05-3377

M3 - Article

C2 - 16452233

AN - SCOPUS:32944467254

VL - 66

SP - 1730

EP - 1739

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 3

ER -